First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
- PMID: 24117165
- PMCID: PMC3976620
- DOI: 10.1111/bph.12461
First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
Abstract
A decline in energy is common in aging, and the restoration of mitochondrial bioenergetics may offer a common approach for the treatment of numerous age-associated diseases. Cardiolipin is a unique phospholipid that is exclusively expressed on the inner mitochondrial membrane where it plays an important structural role in cristae formation and the organization of the respiratory complexes into supercomplexes for optimal oxidative phosphorylation. The interaction between cardiolipin and cytochrome c determines whether cytochrome c acts as an electron carrier or peroxidase. Cardiolipin peroxidation and depletion have been reported in a variety of pathological conditions associated with energy deficiency, and cardiolipin has been identified as a target for drug development. This review focuses on the discovery and development of the first cardiolipin-protective compound as a therapeutic agent. SS-31 is a member of the Szeto-Schiller (SS) peptides known to selectively target the inner mitochondrial membrane. SS-31 binds selectively to cardiolipin via electrostatic and hydrophobic interactions. By interacting with cardiolipin, SS-31 prevents cardiolipin from converting cytochrome c into a peroxidase while protecting its electron carrying function. As a result, SS-31 protects the structure of mitochondrial cristae and promotes oxidative phosphorylation. SS-31 represents a new class of compounds that can recharge the cellular powerhouse and restore bioenergetics. Extensive animal studies have shown that targeting such a fundamental mechanism can benefit highly complex diseases that share a common pathogenesis of bioenergetics failure. This review summarizes the mechanisms of action and therapeutic potential of SS-31 and provides an update of its clinical development programme.
Keywords: SS-31; Szeto-Schiller peptides; bendavia; cytochrome c; cytochrome c peroxidase; mitochondria cristae; mitochondrial permeability transition; oxidative stress; reactive oxygen species.
© 2013 The British Pharmacological Society.
Figures
Similar articles
-
Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis.Br J Pharmacol. 2014 Apr;171(8):2017-28. doi: 10.1111/bph.12468. Br J Pharmacol. 2014. PMID: 24134698 Free PMC article.
-
The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.J Am Soc Nephrol. 2013 Jul;24(8):1250-61. doi: 10.1681/ASN.2012121216. Epub 2013 Jul 11. J Am Soc Nephrol. 2013. PMID: 23813215 Free PMC article.
-
Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis.Am J Physiol Renal Physiol. 2014 May 1;306(9):F970-80. doi: 10.1152/ajprenal.00697.2013. Epub 2014 Feb 19. Am J Physiol Renal Physiol. 2014. PMID: 24553434
-
Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging.Arch Biochem Biophys. 2018 Dec 15;660:137-148. doi: 10.1016/j.abb.2018.10.013. Epub 2018 Oct 23. Arch Biochem Biophys. 2018. PMID: 30359579 Review.
-
Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.Clin Pharmacol Ther. 2014 Dec;96(6):672-83. doi: 10.1038/clpt.2014.174. Epub 2014 Sep 4. Clin Pharmacol Ther. 2014. PMID: 25188726 Free PMC article. Review.
Cited by
-
New Insights into Antioxidant Peptides: An Overview of Efficient Screening, Evaluation Models, Molecular Mechanisms, and Applications.Antioxidants (Basel). 2024 Feb 5;13(2):203. doi: 10.3390/antiox13020203. Antioxidants (Basel). 2024. PMID: 38397801 Free PMC article. Review.
-
Role of Mitochondrial ROS for Calcium Alternans in Atrial Myocytes.Biomolecules. 2024 Jan 24;14(2):144. doi: 10.3390/biom14020144. Biomolecules. 2024. PMID: 38397381 Free PMC article.
-
Biomaterials Functionalized with Inflammasome Inhibitors-Premises and Perspectives.J Funct Biomater. 2024 Jan 28;15(2):32. doi: 10.3390/jfb15020032. J Funct Biomater. 2024. PMID: 38391885 Free PMC article. Review.
-
Fabry Disease: Cardiac Implications and Molecular Mechanisms.Curr Heart Fail Rep. 2024 Apr;21(2):81-100. doi: 10.1007/s11897-024-00645-1. Epub 2024 Jan 30. Curr Heart Fail Rep. 2024. PMID: 38289538 Free PMC article. Review.
-
A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging.NPJ Aging. 2024 Jan 23;10(1):9. doi: 10.1038/s41514-024-00135-7. NPJ Aging. 2024. PMID: 38263284 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
